Murlentamab GM102: An New Antibody in Trial Development Murlentamab GM102 represents an exciting approach for treating relapsed multiple myeloma . This designed monoclonal molecule specifically targets myeloma antigen expressed on cancerous cells, inducing immune-mediated cytotoxic cytotoxicity . Early trial results demonstrate preliminar